Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Is Taltz® (ixekizumab) safe to use in lactation?
It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion.
UK_cFAQ_IXE009_X2_LACTATION_PsO_PsA_axSpA
en-GB
What are the data on the ixekizumab use while breastfeeding?
It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion. However, ixekizumab is excreted at low levels in the milk of cynomolgus monkeys.1
Administer ixekizumab to a nursing woman, only if the potential benefit to the mother justifies the potential risk to the infant.2
Published data suggest that antibodies are excreted in human milk but do not enter the neonatal and infant circulation in substantial amounts.3-5
A decision should be made whether to discontinue breast-feeding or to discontinue ixekizumab taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.1
References
1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Van de Perre P. Transfer of antibody via mother's milk. Vaccine. 2003;21(24):3374-3376. http://dx.doi.org/10.1016/S0264-410X(03)00336-0
4Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104(1):228-233. https://journals.lww.com/ajg/Fulltext/2009/01000/Placental_Transport_of_Immunoglobulins__A_Clinical.37.aspx
5Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients. 2011;3(4):442-474. http://dx.doi.org/10.3390/nu3040442
Date of Last Review: 09 November 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays